MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 154 filers reported holding MERSANA THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,022 | -59.0% | 24,427 | +6.3% | 0.00% | -100.0% |
| Q2 2023 | $75,594 | -20.5% | 22,977 | -0.7% | 0.00% | 0.0% |
| Q1 2023 | $95,056 | -26.0% | 23,128 | +5.4% | 0.00% | 0.0% |
| Q4 2022 | $128,539 | -10.1% | 21,935 | +4.0% | 0.00% | 0.0% |
| Q3 2022 | $143,000 | +50.5% | 21,086 | +3.0% | 0.00% | 0.0% |
| Q2 2022 | $95,000 | +53.2% | 20,481 | +31.7% | 0.00% | – |
| Q1 2022 | $62,000 | -35.4% | 15,551 | +0.6% | 0.00% | -100.0% |
| Q4 2021 | $96,000 | -32.9% | 15,451 | +1.9% | 0.00% | 0.0% |
| Q3 2021 | $143,000 | -29.2% | 15,158 | +1.8% | 0.00% | -50.0% |
| Q2 2021 | $202,000 | -21.7% | 14,896 | -6.6% | 0.00% | 0.0% |
| Q1 2021 | $258,000 | -38.9% | 15,952 | +0.5% | 0.00% | -50.0% |
| Q4 2020 | $422,000 | +47.0% | 15,873 | +2.9% | 0.00% | +33.3% |
| Q3 2020 | $287,000 | +23.2% | 15,423 | +54.6% | 0.00% | 0.0% |
| Q2 2020 | $233,000 | – | 9,978 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $40,026,000 | 4.69% |
| Opaleye Management Inc. | 1,047,000 | $4,837,000 | 2.18% |
| Sarissa Capital Management LP | 4,299,297 | $19,863,000 | 2.00% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $4,178,000 | 1.58% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 850,000 | $3,927,000 | 1.21% |
| Orbimed Advisors | 9,011,437 | $41,633,000 | 0.75% |
| Avoro Capital Advisors LLC | 7,550,000 | $34,881,000 | 0.69% |
| Rock Springs Capital Management LP | 4,075,958 | $18,831,000 | 0.55% |
| Artal Group S.A. | 2,200,000 | $10,164,000 | 0.54% |
| DAFNA Capital Management LLC | 406,763 | $1,879,000 | 0.51% |